RSPI (RespireRx Pharmaceuticals) OCF Margin %: 0.00% (As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals OCF Margin %?

RespireRx Pharmaceuticals RSPI 12 OCF Margin % is 0.00% as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. RespireRx Pharmaceuticals's Cash Flow from Operations for the three months ended in Sep. 2023 was $-0.10 Mil. RespireRx Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, RespireRx Pharmaceuticals's OCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, RespireRx Pharmaceuticals's current OCF Yield % is -29.21%.

The historical rank and industry rank for RespireRx Pharmaceuticals's OCF Margin % or its related term are showing as below:


RSPI's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

RespireRx Pharmaceuticals OCF Margin % Related Terms

RespireRx Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals OCF Margin % Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

RespireRx Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-0.144/0
= %

RespireRx Pharmaceuticals's OCF Margin for the quarter that ended in Sep. 2023 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.101/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
RespireRx Pharmaceuticals (RSPI) has a OCF Margin % of 0.00% as of Sep. 2023. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' OCF Margin % too high?
RespireRx Pharmaceuticals' current OCF Margin % is 0.00%. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' OCF Margin % compare to CNBX and NAVB?
RespireRx Pharmaceuticals' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current OCF Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price